PL2542535T3 - Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania - Google Patents

Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania

Info

Publication number: PL2542535T3
Authority: PL; Poland
Prior art keywords: forms; dihydrophthalazine; amino; production; sodium salt
Prior art date: 2010-03-01

Application number

PL11710423T

Other languages

English (en)

Inventor

Josef Breu

Wolfgang Brysch

Astrid Kaiser

Beate Ludescher

Gerrit Maass

Thomas Martin

Wolfgang Milius

Michael Niedermaier

Original Assignee

Metriopharm Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-01

Filing date

2011-03-01

Publication date

2014-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43828190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2542535(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-01 Application filed by Metriopharm Ag filed Critical Metriopharm Ag

2014-10-31 Publication of PL2542535T3 publication Critical patent/PL2542535T3/pl

Links

JKEBMURXLKGPLR-UHFFFAOYSA-N 5-amino-2,3-dihydrophthalazine-1,4-dione;sodium Chemical compound [Na].O=C1NNC(=O)C2=C1C(N)=CC=C2 JKEBMURXLKGPLR-UHFFFAOYSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000000825 pharmaceutical preparation Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
AIDS & HIV (AREA)
Neurosurgery (AREA)

PL11710423T 2010-03-01 2011-03-01 Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania PL2542535T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP10002067		2010-03-01
EP10075744		2010-11-25
EP11710423.2A EP2542535B1 (de)	2010-03-01	2011-03-01	Kristalline formen von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
PCT/EP2011/001124 WO2011107295A1 (de)	2010-03-01	2011-03-01	Kristalline formen zu 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung

Publications (1)

Publication Number	Publication Date
PL2542535T3 true PL2542535T3 (pl)	2014-10-31

Family

ID=43828190

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11710423T PL2542535T3 (pl)	2010-03-01	2011-03-01	Formy krystaliczne soli sodowej 5-amino-2,3-dihydroftalazyno-1,4-dionu, kompozycje farmaceutyczne je zawierające i sposoby ich wytwarzania

Country Status (23)

Country	Link
US (2)	US8772294B2 (pl)
EP (2)	EP2774920A1 (pl)
JP (2)	JP6061081B2 (pl)
KR (1)	KR101770011B1 (pl)
CN (3)	CN105859634B (pl)
AU (1)	AU2011223226B2 (pl)
BR (1)	BR112012021857B1 (pl)
CA (1)	CA2791327C (pl)
CH (1)	CH704794B1 (pl)
CY (1)	CY1115585T1 (pl)
DK (1)	DK2542535T3 (pl)
ES (1)	ES2487221T3 (pl)
HK (1)	HK1223836A1 (pl)
HR (1)	HRP20140752T1 (pl)
IL (1)	IL221680A (pl)
NZ (1)	NZ601689A (pl)
PL (1)	PL2542535T3 (pl)
PT (1)	PT2542535E (pl)
RS (1)	RS53492B1 (pl)
RU (1)	RU2585677C2 (pl)
SI (1)	SI2542535T1 (pl)
WO (1)	WO2011107295A1 (pl)
ZA (1)	ZA201206264B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2542535E (pt)	2010-03-01	2014-08-25	Metriopharm Ag	Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas
JP2017537958A (ja) *	2014-12-18	2017-12-21	メトリオファームアーゲー	５−アミノ−２，３−ジヒドロフタラジン１，４−ジオンナトリウム塩の結晶形態、同一物を含む医薬製剤、及びこの形態の製造ための方法
CN109563052A (zh) *	2016-02-16	2019-04-02	麦翠奥制药公司	5-氨基-2,3-二氢噻嗪-1,4-二酮的结晶体
WO2017140422A1 (en) *	2016-02-16	2017-08-24	Metriopharm Ag	Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione
EP3248602A1 (en)	2016-05-26	2017-11-29	MetrioPharm AG	Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
RU2625267C1 (ru) *	2016-09-22	2017-07-12	Общество с ограниченной ответственностью "АБИДАФАРМА"	Способ производства нестерильных субстанций безводного "тамерита" и/или двухводного "галавита" - натриевых солей 5-амино-2,3-дигидрофталазин-1,4-диона (варианты) и способы дальнейшей их переработки в стерильные лекарственные препараты
DK3534904T3 (da)	2016-11-07	2022-04-11	Metriopharm Ag	Anvendelse af 5-amino-2,3-dihydro-1,4-phthalazindion i behandlingen af kronisk progressiv multipel sklerose
CN106810501B (zh) *	2017-01-23	2019-09-10	湖北新德晟材料科技有限公司	一种利用一锅法合成鲁米诺或异鲁米诺的方法
RU2635769C1 (ru) *	2017-02-08	2017-11-15	Адмир Мусаевич Абидов	Лекарственный препарат на основе 5-амино-2,3-дигидрофталазин-1,4-диона в виде быстрорастворимой пленки для трансбуккального введения
RU2673452C1 (ru) *	2017-08-15	2018-11-27	Межрегиональное общественное учреждение "Институт инженерной физики"	Способ получения активной фармацевтической субстанции, представляющей собой аминодигидрофталазиндион натрия
EP3511325A1 (en)	2018-01-11	2019-07-17	MetrioPharm AG	Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175B1 (en) *	2018-10-26	2024-08-28	Immunopharma Plus D.O.O.	Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858358A1 (en)	2020-01-31	2021-08-04	MetrioPharm AG	Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases
EP3858328A1 (en)	2020-01-31	2021-08-04	MetrioPharm AG	Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
PL4125802T3 (pl) *	2020-03-25	2026-03-23	Metriopharm Ag	5-amino-2,3-dihydro-1,4-ftalazinedion do leczenia ostrego uszkodzenia płuc
EP3981405A1 (en)	2020-10-08	2022-04-13	MetrioPharm AG	Compound for the treatment of coronaviral infections
AU2021288757B2 (en)	2020-06-10	2026-01-08	Metriopharm Ag	Compound for the treatment of coronaviral infections
AU2021304254B9 (en)	2020-07-09	2025-07-10	Metriopharm Ag	Glucocorticoid-sparing agent
US20240075029A1 (en)	2020-12-02	2024-03-07	Metriopharm Ag	Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection
RU2756568C1 (ru) *	2021-03-24	2021-10-01	Акционерное общество "Щелково Агрохим"	Способ получения натриевой соли 5-амино-2,3-дигидро-1,4-фталазиндиона в гидратированной или безводной форме
EP4193994A1 (en)	2021-12-08	2023-06-14	MetrioPharm AG	Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections
EP4209219A1 (en)	2022-01-07	2023-07-12	MetrioPharm AG	Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione
EP4248963A1 (en)	2022-03-25	2023-09-27	MetrioPharm AG	Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a fumaric acid ester
EP4483879A1 (en)	2023-06-29	2025-01-01	MetrioPharm AG	5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
EP4784132A1 (en)	2023-09-26	2026-08-05	MetrioPharm AG	5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1089086C (zh) *	1988-03-31	2002-08-14	兰德尔·L·米尔斯	鲁米纳得类药物
CH683966A5 (it) *	1993-02-19	1994-06-30	Limad Marketing Exp & Imp	Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa.
CH683965A5 (it)	1993-02-19	1994-06-30	Limad Marketing Exp & Imp	Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
RU2113222C1 (ru)	1997-09-30	1998-06-20	Закрытое акционерное общество "Центр современной медицины "Медикор"	Иммуномодулирующее средство
RU2138264C1 (ru)	1999-05-06	1999-09-27	Абидов Муса Тажудинович	Способ получения лекарственного препарата галавит
US6489326B1 (en)	2000-03-28	2002-12-03	Anatoliy Ivanovich Pavlov	Medicinal preparation and process for manufacturing thereof
RU2167659C1 (ru)	2000-08-02	2001-05-27	Закрытое акционерное общество "Центр современной медицины "Медикор"	Способ коррекции иммунной системы живого организма
RU2169139C1 (ru)	2000-08-02	2001-06-20	Закрытое акционерное общество "Центр современной медицины "Медикор"	Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона
RU2211036C2 (ru)	2001-11-20	2003-08-27	Общество с ограниченной ответственностью "Абидофарма"	Лекарственный препарат (варианты) и способ его производства
RU2222327C2 (ru)	2002-03-22	2004-01-27	Общество с ограниченной ответственностью "Абидофарма"	Способ получения лекарственного препарата
US7326690B2 (en)	2002-10-30	2008-02-05	Bach Pharma, Inc.	Modulation of cell fates and activities by phthalazinediones
RU2238730C1 (ru)	2003-02-17	2004-10-27	Абидов Муса Тажудинович	Лекарственный препарат
RU2302863C2 (ru)	2003-04-18	2007-07-20	Общество с ограниченной ответственностью "Абидофарма"	Лекарственный препарат (варианты)
CN1217193C (zh) *	2003-07-30	2005-08-31	中国药科大学	心肌肌钙蛋白鲁米诺化学发光免疫分析检测方法
EP1655301B1 (en)	2003-08-04	2015-03-11	Valery Khazhmuratovich Zhilov	Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
PL231885B1 (pl)	2009-01-16	2019-04-30	Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia	Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
WO2010091257A1 (en)	2009-02-06	2010-08-12	Bach Pharma, Inc.	Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them
PT2542535E (pt) *	2010-03-01	2014-08-25	Metriopharm Ag	Formas cristalinas para sal de sódio de 5-amino-2,3-di hidroftalazino-1,4-diona, preparações farmacêuticas contendo o mesmo e processo para a produção das ditas formas

2011
- 2011-03-01 PT PT117104232T patent/PT2542535E/pt unknown
- 2011-03-01 PL PL11710423T patent/PL2542535T3/pl unknown
- 2011-03-01 CN CN201610087179.8A patent/CN105859634B/zh active Active
- 2011-03-01 CH CH01123/12A patent/CH704794B1/de not_active IP Right Cessation
- 2011-03-01 CA CA2791327A patent/CA2791327C/en active Active
- 2011-03-01 US US13/582,522 patent/US8772294B2/en active Active
- 2011-03-01 SI SI201130233T patent/SI2542535T1/sl unknown
- 2011-03-01 HR HRP20140752AT patent/HRP20140752T1/hr unknown
- 2011-03-01 RU RU2012141274/04A patent/RU2585677C2/ru active
- 2011-03-01 RS RSP20140416 patent/RS53492B1/sr unknown
- 2011-03-01 JP JP2012555335A patent/JP6061081B2/ja active Active
- 2011-03-01 WO PCT/EP2011/001124 patent/WO2011107295A1/de not_active Ceased
- 2011-03-01 KR KR1020127025234A patent/KR101770011B1/ko active Active
- 2011-03-01 AU AU2011223226A patent/AU2011223226B2/en active Active
- 2011-03-01 NZ NZ601689A patent/NZ601689A/en unknown
- 2011-03-01 DK DK11710423.2T patent/DK2542535T3/da active
- 2011-03-01 BR BR112012021857-3A patent/BR112012021857B1/pt active IP Right Grant
- 2011-03-01 CN CN201180011760.7A patent/CN102971300B/zh active Active
- 2011-03-01 ES ES11710423.2T patent/ES2487221T3/es active Active
- 2011-03-01 CN CN201610087203.8A patent/CN105726541A/zh active Pending
- 2011-03-01 EP EP14001134.7A patent/EP2774920A1/de not_active Withdrawn
- 2011-03-01 EP EP11710423.2A patent/EP2542535B1/de active Active
2012
- 2012-08-20 ZA ZA2012/06264A patent/ZA201206264B/en unknown
- 2012-08-29 IL IL221680A patent/IL221680A/en active IP Right Grant
2014
- 2014-04-08 US US14/247,626 patent/US9079863B2/en active Active
- 2014-08-04 CY CY20141100589T patent/CY1115585T1/el unknown
2016
- 2016-06-09 JP JP2016115125A patent/JP6206689B2/ja active Active
- 2016-10-24 HK HK16112162.9A patent/HK1223836A1/zh unknown

Also Published As

Publication number	Publication date
IL221680A (en)	2015-09-24
HK1223836A1 (zh)	2017-08-11
US20140303169A1 (en)	2014-10-09
SI2542535T1 (sl)	2014-09-30
CN105859634B (zh)	2019-06-28
RU2585677C2 (ru)	2016-06-10
CN105726541A (zh)	2016-07-06
RS53492B1 (sr)	2015-02-27
EP2774920A1 (de)	2014-09-10
CH704794B1 (de)	2013-04-15
HRP20140752T1 (hr)	2014-10-24
WO2011107295A1 (de)	2011-09-09
US8772294B2 (en)	2014-07-08
ES2487221T3 (es)	2014-08-20
KR20130019383A (ko)	2013-02-26
NZ601689A (en)	2014-11-28
KR101770011B1 (ko)	2017-08-21
IL221680A0 (en)	2012-12-02
JP6061081B2 (ja)	2017-01-18
BR112012021857B1 (pt)	2021-06-22
CN102971300A (zh)	2013-03-13
PT2542535E (pt)	2014-08-25
JP2013521239A (ja)	2013-06-10
AU2011223226B2 (en)	2015-04-23
JP2016196483A (ja)	2016-11-24
CN102971300B (zh)	2016-03-02
AU2011223226A1 (en)	2012-10-25
DK2542535T3 (da)	2014-07-28
CN105859634A (zh)	2016-08-17
ZA201206264B (en)	2016-07-27
CY1115585T1 (el)	2017-01-04
HK1223929A1 (zh)	2017-08-11
CA2791327C (en)	2018-10-30
EP2542535A1 (de)	2013-01-09
BR112012021857A2 (pt)	2016-05-17
US20120329801A1 (en)	2012-12-27
US9079863B2 (en)	2015-07-14
EP2542535B1 (de)	2014-05-07
RU2012141274A (ru)	2014-04-20
CA2791327A1 (en)	2011-09-09
JP6206689B2 (ja)	2017-10-04

Publication	Publication Date	Title
IL221680A0 (en)	2012-12-02	Crystalline forms for 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said forms
ZA201301799B (en)	2014-05-28	Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
AP3222A (en)	2015-04-30	Germination-stimulant carbamate derivatives and process for preparation thereof
EP2665716A1 (en)	2013-11-27	Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
PL3210991T3 (pl)	2020-03-31	Postać krystaliczna lewoizowalerylospiramycyny II oraz preparaty, sposoby wytwarzania i ich zastosowanie
PL3586632T3 (pl)	2023-01-30	Pochodne 10H-benzo[g]pterydyno-2,4-dionu, sposób ich wytwarzania i ich zastosowanie
SI2281822T1 (sl)	2013-04-30	Novi derivati dihidroindolona, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
ZA201500362B (en)	2016-01-27	Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL221461A0 (en)	2012-10-31	Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
GB2495458B (en)	2016-03-09	Crystals of carboprost tromethamine and the preparation method as well as the uses thereof
EP2709455A4 (en)	2014-11-05	PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES
ZA201303467B (en)	2014-07-30	Method for the preparation of high-purity pharmaceutical intermediates
IL233199A0 (en)	2014-08-03	History of heterocyclic carboxamides, their preparation and pharmaceutical preparations containing them
IL248698B (en)	2018-10-31	History of 1-h-pyrrolidine-4,2-dione and processes for their preparation
IL230907A0 (en)	2014-03-31	Salt and formations of a pyrazolopyrimidine compound, a medical composition that includes the above, and a preparation and use process for them
HU1000565D0 (en)	2010-12-28	Process for the preparation of pharmaceutically active compound and intermediers
WO2012018791A3 (en)	2012-08-23	Preparation of prasugrel hydrochloride
EP2642855A4 (en)	2014-05-28	INTERMEDIATE COMPOUNDS AND METHOD FOR THE PREPARATION OF CHINOLIN DERIVATIVES SUCH AS LAQUINIMOD SODIUM
EP2896625A4 (en)	2016-03-16	COCRISTAL OF PIPERACILLIN-SODIUM AND SULBACTAM-SODIUM AND METHOD OF MANUFACTURING THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
EP2598485A4 (en)	2014-07-30	NEW MONTELUKAST 4-HALOGENOBENZYLAMINE SALT AND PROCESS FOR PREPARING MONTELUKAST SODIUM SALT USING THE SAME
WO2013114397A3 (en)	2013-10-17	Pharmaceutically acceptable salt of brinzolamide and composition thereof
EP2581375A4 (en)	2014-02-19	IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES
PL392283A1 (pl)	2012-03-12	Nowe pochodne aldehydu lub kwasu 4-cykloheksylo-5-nitro-2-oksopentanowego, sposób ich wytwarzania oraz ich zastosowanie
PL2607354T3 (pl)	2014-10-31	Nowy sposób syntezy iwabradyny i jej soli addycyjnych z kwasem farmaceutycznie dopuszczalnym
PL391018A1 (pl)	2011-10-24	Sole pochodnych cystein i sposób wytwarzania soli pochodnych cystein